Anthrax vaccine - Emergent BioSolutions

Drug Profile

Anthrax vaccine - Emergent BioSolutions

Alternative Names: Oral anthrax vaccine - Emergent BioSolutions

Latest Information Update: 14 Aug 2009

Price : $50

At a glance

  • Originator Emergent BioSolutions
  • Class Anthrax vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Anthrax

Most Recent Events

  • 04 Sep 2006 No development reported - Preclinical for Anthrax in United Kingdom (PO)
  • 27 Jun 2005 Microscience has been acquired by Emergent BioSolutions
  • 05 Aug 2003 Preclinical trials in Anthrax in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top